Infliximab: adverse events as reason for treatment discontinuation

被引：0
作者：
Moustou, A. -E. [1 ]
Papoutsaki, M. [1 ]
Vergou, T. [1 ]
Masouri, S. [1 ]
Sachlas, A. [2 ]
Antoniou, C. [1 ]
机构：
[1] A Sygros Hosp, Dept Dermatol 1, Athens, Greece
[2] Univ Peloponnese, Dept Nursing, Sparta, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
adverse events; infliximab; treatment discontinuation;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P184
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [41] Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: A propensity score analysis
    Kwon, Yong Shik
    Han, Minkyu
    Kwon, Byoung Soo
    Kim, Ock-Hwa
    Lee, Ho-Young
    Shim, Tae Sun
    Chong, Yong Pil
    Jo, Kyung-Wook
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 22 : 106 - 112
  • [42] Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission
    Nawata, Masao
    Saito, Kazuyoshi
    Nakayamada, Shingo
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2008, 18 (05) : 460 - 464
  • [43] Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD
    Upadhyaya, Himanshu
    Tanaka, Yoko
    Lipsius, Sarah
    Kryzhanovskaya, Ludmila A.
    Lane, Jeannine R.
    Escobar, Rodrigo
    Trzepacz, Paula T.
    Allen, Albert J.
    POSTGRADUATE MEDICINE, 2015, 127 (07) : 677 - 685
  • [44] Adverse events and nocebo phenomena: treatment or disease specific?
    Zis, Panagiotis
    Sykioti, Panagiota
    BMC MEDICINE, 2019, 17 (1)
  • [45] Levofloxacin treatment of active tuberculosis and the risk of adverse events
    Marra, F
    Marra, CA
    Moadebi, S
    Shi, P
    Elwood, RK
    Stark, G
    FitzGerald, JM
    CHEST, 2005, 128 (03) : 1406 - 1413
  • [46] Adverse events and nocebo phenomena: treatment or disease specific?
    Panagiotis Zis
    Panagiota Sykioti
    BMC Medicine, 17
  • [47] Ipilimumab in the treatment of metastatic melanoma: management of adverse events
    Scarpati, Giuseppina Della Vittoria
    Fusciello, Celeste
    Perri, Francesco
    Sabbatino, Francesco
    Ferrone, Soldano
    Carlomagno, Chiara
    Pepe, Stefano
    ONCOTARGETS AND THERAPY, 2014, 7 : 203 - 209
  • [48] Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study
    Kadokawa, Yukio
    Takagi, Mari
    Yoshida, Tomoe
    Tatsumi, Akitoshi
    Fujita, Keiko
    Inoue, Takako
    Ohe, Shuichi
    Nakai, Yasutomo
    Yamamoto, Sachiko
    Otsuka, Tomoyuki
    Ishihara, Ryu
    Isei, Taiki
    Kumagai, Toru
    Nishimura, Kazuo
    Imamura, Fumio
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (04) : 1 - 12
  • [49] Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
    Veisman, Ido
    Barzilay, Oranit
    Bruckmayer, Liora
    Haj-Natour, Ola
    Kopylov, Uri
    Eliakim, Rami
    Ben-Horin, Shomron
    Ungar, Bella
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (18)
  • [50] Neuropsychiatric adverse events of bupropion treatment: a brief update
    Soyka, M
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2004, 8 (04) : 251 - 254
12345